Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Stock analysts at FBR & Co issued their FY2021 earnings estimates for shares of Supernus Pharmaceuticals in a research report issued on Monday. FBR & Co analyst D. Buck anticipates that the specialty pharmaceutical company will earn $4.00 per share for the year. FBR & Co currently has a “Buy” rating and a $53.00 target price on the stock.

Several other research firms have also issued reports on SUPN. Stifel Nicolaus lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price target for the company. in a research report on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies reissued a “hold” rating and issued a $41.00 price target on shares of Supernus Pharmaceuticals in a research report on Tuesday, September 26th. BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $49.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Jefferies Group LLC increased their price target on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, June 28th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $48.38.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/25/supernus-pharmaceuticals-inc-supn-forecasted-to-post-fy2021-earnings-of-4-00-per-share.html.

Supernus Pharmaceuticals (SUPN) traded down 0.12% during trading on Wednesday, hitting $41.50. The stock had a trading volume of 276,981 shares. The company has a market cap of $2.10 billion, a PE ratio of 20.94 and a beta of 1.30. Supernus Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $50.04. The stock has a 50-day moving average price of $42.64 and a 200-day moving average price of $40.00.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Supernus Pharmaceuticals by 0.5% during the second quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock worth $289,962,000 after buying an additional 31,331 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Supernus Pharmaceuticals by 39.1% during the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after buying an additional 984,200 shares in the last quarter. State Street Corp increased its holdings in shares of Supernus Pharmaceuticals by 3.1% during the second quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after buying an additional 42,165 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in shares of Supernus Pharmaceuticals by 24.5% during the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock worth $58,675,000 after buying an additional 267,971 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Supernus Pharmaceuticals by 10.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock worth $54,654,000 after buying an additional 122,042 shares in the last quarter. 94.71% of the stock is owned by institutional investors.

In other news, SVP Padmanabh P. Bhatt sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $49.86, for a total transaction of $249,300.00. Following the completion of the sale, the senior vice president now owns 12,500 shares of the company’s stock, valued at $623,250. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $45.23, for a total transaction of $167,758.07. Following the sale, the vice president now directly owns 17,500 shares of the company’s stock, valued at approximately $791,525. The disclosure for this sale can be found here. Insiders sold 153,709 shares of company stock valued at $7,223,108 in the last three months. Company insiders own 6.70% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.